Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 121Other hematologic neoplasm 15Lymphoid 15Genitourinary 5Thoracic 2Myeloid 2CNS 2Breast 2Other neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × daratumumab × Thoracic × Clear all
NCT06015724 2026-05-15

DARANIVOVAX

Georgetown University

Phase 2 Recruiting
54 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05807048 2026-03-10

Daratumumab in STK11 Mutated NSCLC

NYU Langone Health

Phase 2 Completed
8 enrolled
Thoracic

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡